Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?

Basit Öğe Kaydı
dc.authoridsensu, sibel/0000-0002-4607-780X
dc.authorwosidHallaç Keser, Sevinç/KUD-5074-2024
dc.authorwosidsensu, sibel/AGU-9782-2022
dc.contributor.authorErhan, Selma Sengiz
dc.contributor.authorSensu, Sibel
dc.contributor.authorKeser, Sevinc Hallac
dc.contributor.authorKangal, Elis
dc.contributor.authorGul, Aylin Ege
dc.contributor.authorGundogan, Gokcen Alinak
dc.contributor.authorSakin, Abdullah
dc.date.accessioned2024-08-04T21:00:01Z
dc.date.available2024-08-04T21:00:01Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives: In gastrointestinal stromal tumors (GIST), malignancy potential is determined by the prognostic disease risk stratification based on mitosis, tumor size, and location. Phosphohistone H3 (PHH3) is an immunohistochemical marker showing mitotic activity in cells. In this study, we aimed to evaluate mitosis in GIST with PHH3, compare the results with hematoxylin and eosin (HE) stained slides, and examine its relationship with other prognostic data. Methods: Clinicopathological findings and survival were determined in GIST cases diagnosed between 2006 and 2017. The prognostic risk score was calculated according HE- and PHH3-based mitosis. The cases were classified as Group I: HE + and PHH3 + and Group II: HE + and PHH3-. They were also grouped as those diagnosed before and after 2012 and the staining results of HE and PHH3 were re-analyzed. Results: Ninety-eight cases were included in the study. Mitosis was detected with both HE and PHH3 in 63.3% of the cases (62/98 cases) (Group I) while in 36.7% of cases, it was detected with HE but not with PHH3 (Group II). In only two cases, the risk score changed with PHH3 (very low -> intermedier grade). The ratio of HE + and PHH3 + cases in 2012 and after was significantly higher than HE + and PHH3 - cases. A statistically significant relation was found between HE- and PHH3-based risk scores (p<0.05). There was a significant difference between HE-based risk score groups in terms of survival (p<0.05), while no difference was observed between the PHH3-based risk score groups (p>0.05). Conclusion: In GIST cases, PHH3 can be used to determine mitosis in more recent blocks, taking into account the technical conditions of the laboratory, but it does not seem to be superior to mitosis detected by HE. Research should continue on new survival determinants for GIST.en_US
dc.identifier.doi10.14744/SEMB.2021.32798
dc.identifier.endpage283en_US
dc.identifier.issn1302-7123
dc.identifier.issn1308-5123
dc.identifier.issue2en_US
dc.identifier.pmid35990307en_US
dc.identifier.startpage276en_US
dc.identifier.urihttps://doi.org/10.14744/SEMB.2021.32798
dc.identifier.urihttps://hdl.handle.net/11616/103700
dc.identifier.volume56en_US
dc.identifier.wosWOS:000823035600017en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofMedical Bulletin of Sisli Etfal Hospitalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastrointestinal stromal tumoren_US
dc.subjectrisk scoreen_US
dc.subjectmitosisen_US
dc.subjectphosphohistone H3en_US
dc.titleMitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu